HNSCC
Oncology · 2007–2025
12decisions
4medicines
9carried consumer input
25individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Perioperative treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) of the oral cavity, pharynx or larynx,… | Nov 2025 | Recommended with restriction | 2 individuals Neck Cancer Australia · Rare Cancers Australia |
| pembrolizumab First-line treatment of previously untreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, pharynx or larynx in… | Mar 2022 | Recommended | 3 individuals |
| pembrolizumab First-line treatment of previously untreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, pharynx and larynx in… | Nov 2021 | Deferred | 3 individuals |
| pembrolizumab First-line treatment of recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx, and larynx (HNSCC) in patients whose tumours express PD-L1… | Nov 2020 | Recommended with restriction | 2 individuals Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab Treatment of patients with locally advanced (Stage III) or metastatic (Stage IV) squamous cell carcinoma of the head and neck (SCCHN) who have failed a… | Jul 2018 | Not recommended | 11 individuals |
| cetuximab Treatment of patients with previously untreated recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM SCCHN) in combination with… | Mar 2018 | Recommended with restriction | 1 individuals |
| nivolumab Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx in patients who have progressed within 6 months after platinum-based… | Mar 2018 | Recommended with restriction | 2 individuals |
| nivolumab Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx who have progressed within 6 months after platinum-based chemotherapy. | Nov 2017 | Recommended with restriction | 1 individuals Rare Cancers Australia |
| cetuximab Treatment of patients with previously untreated metastatic and/or recurrent squamous cell carcinoma of the head and neck (RM SCCHN), in combination with… | Nov 2016 | Not recommended | input received Rare Cancers Australia |
| docetaxel Induction treatment of locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil (PF). | Jul 2008 | Recommended with restriction | no section in document |
| docetaxel Induction treatment of locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil (PF). | Jul 2008 | Recommended with restriction | no section in document |
| cetuximab Treatment in combination with radiotherapy, of patients with UICC Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx in whom… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Rare Cancers Australia · Medical Oncology Group · Neck Cancer Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 9 of 9 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.